[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PT. Prodia Stem Cell Indonesia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,92,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100626762","phase-1-mesenchymal-stem-cells-mscs-and-conditioned-medium-mesenchymal-stem-cells-as-adjuvant-therapy-for-sepsis-100626762",false,"NCT07439848","Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis","A Randomized, Double-Blind, Controlled Trial Evaluating the Potential of Mesenchymal Stem Cells and Their Secretome as Adjuvant Therapy to Reduce Length of Hospital Stay and Mortality in Patients With Sepsis Due to Pneumonia","Inclusion Criteria:\n\n* Male or female at least 40 years old when the Informed Consent Form (ICF) is signed by the family, as evidenced by an identity card.\n* Patients with severe ARDS according to Berlin criteria\n* Families are willing to participate in clinical trial procedures including not participating in other clinical trials for the duration of participation.\n\nExclusion Criteria:\n\n* A pregnant woman is proven by a pregnancy test.\n* The results of the SGOT or SGPT examination increased \\> 5 times the upper limit of the normal laboratory value in the hospital.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin, including patients undergoing routine hemodialysis.\n* Having more than 2 of the following co-morbidities; hypertension, diabetes, chronic heart disease, chronic lung disease, COPD, asthma, tuberculosis, cancer, chronic kidney disease, immunosuppressive disease, HIV.\n* The results of the lipid profile are far above normal (what is the cut off number?). Normal cholesterol levels for women aged 20 years and over are 125-200 mg\u002FdL with LDL below 100 mg\u002FdL and HDL above 40 mg\u002FdL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg\u002FdL. Normal cholesterol levels for men aged 20 years or older are 125-200 mg\u002FdL with LDL below 100 mg\u002FdL and HDL above 40 mg\u002FdL. It is said to have high cholesterol when the level in the blood reaches more than 239 mg\u002FdL.\n* PT APTT, C Peptide","ALL","40 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC and Secretome treatment.",[27],"Acute Respiratory Distress Syndrome",[27,29,30],"Mesenchymal Stem Cells","Secretome","RECRUITING","2026-02-23",{"date":34,"type":35},"2026-02-27","ACTUAL",{"date":37,"type":35},"2023-12-25",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"PT. Prodia Stem Cell Indonesia","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100509135","phase-2-role-of-uc-msc-and-cm-to-inhibit-vision-loss-in-retinitis-pigmentosa-phase-iii-100509135","NCT05909488","Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I\u002FII","Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I\u002FII","Inclusion Criteria:\n\n* Visus more than 20\u002F100\n* Have more than 0.68 uV on conical receptor cell amplitude checked by ERG\n* Visual field equivalent diameter more than 10o\n* Willing to sign informed consent as research subjects\n* Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue\n* Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations, and fill out a quality of life questionnaire\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Positive result of HIV test\n* Have a history of eye tumors\n* Under immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells\n* Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma\n* Do not come to control according to the schedule determined by the researcher (loss to follow up)","18 Years","65 Years",{"count":54,"type":20},30,[24,56],"PHASE3","The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.",[59],"Retinitis Pigmentosa",[61,62,63,64],"Allogeneic Mesenchymal Stem Cell","Umbilical Cord Mesenchymal Stem Cell","Conditioned Medium","Allogeneic Umbilical Cord Mesenchymal Stem Cell","NOT_YET_RECRUITING",{"date":67,"type":35},"2026-02-25",{"date":69,"type":20},"2026-05",{"date":71,"type":20},"2027-09",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":90,"locationsCount":91},"100499671","long-term-safety-of-uc-msc-transplantation-in-patients-with-retinitis-pigmentosa-100499671","NCT05786287","Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa","Long-term Safety of Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Transplantation in Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Visual field defects at the initial examination with Humphrey perimetry are between 25% to 50%\n* Willing to sign informed consent as research subjects\n* Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue\n* Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations and fill out a quality of life questionnaire\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Positive result of HIV test\n* Have a history of eye tumours\n* In the immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells\n* Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma\n* Do not come to control according to the schedule determined by the researcher (loss to follow up)",{"count":81,"type":20},18,"OBSERVATIONAL","The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and\u002For CM transplantation.",[59],[61,62,63,64,86],"Safety",{"date":67,"type":35},{"date":69,"type":20},{"date":71,"type":20},{"name":41,"class":42},2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100625947","phase-1-secretome-vs-prp-injections-for-hair-density-and-growth-in-androgenetic-alopecia-patients-100625947","NCT07429253","Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients","Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital","Inclusion Criteria:\n\n* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients who are not currently pregnant or breastfeeding.\n* Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.\n* Patients with no known allergies to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* Patients who are proficient in Indonesian and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Participants who are unable to speak or understand Indonesian and\u002For are unwilling to provide written informed consent.\n* Patients presenting with types of hair loss other than androgenetic alopecia.\n* Patients currently undergoing therapy with 5-alpha reductase inhibitors.\n* Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.\n* Patients with active infections and\u002For active dermatitis on the scalp.\n* Patients with a known history of allergy to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* History of hypertrophic scarring or blood clotting (coagulation) disorders.\n* Patients unable to complete the research procedures in their entirety.","25 Years","59 Years",{"count":102,"type":20},40,[23,24],"This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.",[106],"Androgenetic Alopecia",[30,108,106,109],"Platelet-Rich Plasma","Trichoscopy","2026-02-17",{"date":112,"type":35},"2026-02-24",{"date":114,"type":35},"2026-01-09",{"date":116,"type":20},"2026-09-30",{"name":41,"class":42},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":124,"maxAge":52,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":43},"100623401","phase-1-safety-and-efficacy-of-allogeneic-umbilical-cord-mesenchymal-stem-cell-therapy-in-diabetic-nephropathy-patients-a-clinical-trial-100623401","NCT07396155","Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM)\n* Aged between 40 and 65 years\n* Diagnosed with chronic kidney disease (CKD) stage III or IV, defined as estimated GFR (eGFR) between 15-60 mL\u002Fmin\u002F1.73 m² (using CKD-EPI formula)\n* Renal biopsy showing diabetic nephropathy type IIa-IV\n* Presence of proteinuria, with urine albumin-to-creatinine ratio (UACR) between 30-3000 mg\u002Fg (spot morning urine sample)\n* Controlled diabetes, defined as HbA1c \\\u003C10.0% during screening\n* Blood pressure within the range of: Systolic 100-160 mmHg, Diastolic 60-100 mmHg\n* On stable standard therapy for diabetic nephropathy (e.g. ACE inhibitors or ARBs) for at least 12 weeks prior to screening\n* Willing to provide written informed consent and comply with all study procedures until completion\n\nExclusion Criteria:\n\n* Active malignancy or history of cancer\n* Active liver disease or abnormal liver function (ALT or AST ≥2× upper limit of normal)\n* Hemoglobin \\\u003C8 g\u002FdL or platelet count \\\u003C100,000\u002FµL\n* Serious or unstable cerebrovascular or cardiovascular conditions within the last 6 months\n* Positive pregnancy test or currently breastfeeding (for women of reproductive age)\n* Currently receiving immunosuppressive therapy equivalent to ≥20 mg\u002Fday prednisone\n* History of participation in other stem cell research or therapy studies","30 Years",{"count":126,"type":20},10,[23,24],"The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65 years. The primary questions the study aims to answer are:\n\n1. Is UC-MSC therapy safe and well-tolerated when administered intra-renally in patients with diabetic nephropathy?\n2. Does UC-MSC therapy improve kidney function and modulate inflammatory markers over a 12-month follow-up-period?\n\nThis is a single-arm, open-label, prospective clinical trial. Participants will receive a one-time intra-renal injection of UC-MSC at a dose of 1 x 10⁶ cells\u002Fkg body weight.\n\nParticipants will attend scheduled follow-up visits at 1, 3, 6, 9, and 12 months post-injections for evaluation of:\n\n1. Renal function (eGFR, serum creatinine, and urine albumin-creatinine ratio)\n2. Inflammatory markers (TNF-α, IL-10)\n3. Safety outcomes including early and late adverse events\n\nThe results will be compared to baseline measurements to assess changes after the intervention.\n\nIf there is a comparison group: Researchers will compare \\[arm information\\] to see if \\[insert effects\\].\n\nParticipants will \\[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\\].",[130],"Diabetic Nephropathy Type 2",[62,132,133,134,135,136,137,138,139,29,140],"Diabetic Nephropathy","Kidney Disease","Intra-renal Injection","TNF-alpha","IL-10","Glomerular Filtration Rate","eGFR","Regenerative Medicine","UC-MSC","2026-02-03",{"date":143,"type":35},"2026-02-09",{"date":145,"type":20},"2026-07-01",{"date":147,"type":20},"2027-10",{"name":41,"class":42},""]